Costs Of Overactive Bladder Symptoms Treatment With Solifenacin

Solifenacin significantly improves all symptoms of overactive bladder syndrome

Overactive bladder syndrome (OAB) is a chronic condition characterised by urgency, with or without associated urge incontinence. Solifenacin succinate is a once daily, bladder selective antimuscarinic available in two doses (5 and 10 mg). The recommended dose is 5 mg once daily and can be increased to 10 mg once daily if 5 mg is well tolerated. This article presents pooled efficacy and safety d...

Comparison of solifenacin and fesoterodine in treatment of overactive bladder

OBJECTIVE To compare the use of solifenacin and fesoterodine in treatment of overactive bladder (OAB). METHODS This prospective study was conducted on patients diagnosed with OAB who presenting to the Department of Obstetrics and Gynecology and Urology, School of Medicine, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey between October 2013 and August 2014. Patients were randomized...

Solifenacin: scientific evidence in the treatment of overactive bladder.

OBJECTIVES This article aims to analyse the use of solifenacin in the treatment of overactive bladder in order to show its efficacy and safety within the framework of the scientific evidence. METHODS The available scientific literature was reviewed, including most of the relevant clinical trials performed with solifenacin. RESULTS All the studies analysed show significant improvements in pa...

Solifenacin succinate (VESIcare): overactive bladder therapy.

Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.

BACKGROUND The efficacy of antimuscarinic drug therapy in patients who have more severe symptoms of overactive bladder (OAB) at baseline has not been evaluated thoroughly. OBJECTIVE This analysis determined the effects of solifenacin in patients with severe OAB symptoms at baseline. METHODS All randomized, placebo-controlled phase III studies of solifenacin were pooled to determine the effe...